Equitas Small Finance Bank Fund Raise of ₹1,750 Cr

Equitas Small Finance Bank Earnings Call Transcript: Key Takeaways

Bank crosses ₹1 lakh crore business milestone despite MD P.N. Vasudevan's surprise resignation over family investment conflicts.

Equitas Small Finance Bank Investor Presentation: Key Takeaways

Q2FY27 record PAT Rs218 Cr (vs Rs24 Cr); RoA 1.31%, RoE 13.50%; advances up 30% YoY to Rs50,669 Cr; NIM compressed to 6.69% on surplus liquidity.

Equitas Small Finance Bank Results Update

Equitas Small Finance Bank posted Q2FY27 PAT of ₹218 crore, up 803% YoY. Total business crossed ₹1 lakh crore with advances and deposits each surpassing ₹50,000 crore.

Equitas Small Finance Bank Management Change

Equitas Small Finance Bank's MD & CEO P. N. Vasudevan resigned effective upon successor appointment. The Board will recommend suitable candidates subject to RBI approval.

Equitas Small Finance Bank Q2 FY27 Results: Net Profit ₹218 Cr, Up 804.6% YoY

Equitas Small Finance Bank Ltd reported revenue from operations of ₹2,066 Cr (+27.7% YoY) and net profit of ₹218 Cr (+804.6% YoY) for Q2 FY27.

Key figure

Net profit ₹218 Cr · +804.6% YoY

Equitas Small Finance Bank Other Announcement

The company submitted its quarterly shareholding pattern for the period ending September 30, 2026. This is a periodic regulatory compliance filing required under SEBI listing regulations.

Sudarshan Pharma Industries Fund Raise of ₹72 Cr

Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.

Value

₹72.00 Cr

Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr

Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.

Value

₹68.20 Cr

Kanel Industries Fund Raise of ₹16.99 Cr

Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.

Value

₹16.99 Cr

Execution

Rights issue opens 23 November 2026 and closes 30 November 2026

Sudarshan Pharma Industries Fund Raise

Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.

GAIL (India) Fund Raise

GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.

Gujarat Inject (Kerala) Fund Raise of ₹3 Cr

Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.

Value

₹3.00 Cr